Deep Genomic Profiling in Breast Cancer Promises to Improve Outcomes
0VIENNA—With actionable genomic alterations already being targeted by some existing approved drugs in patients with breast cancer genomic analysis was being hailed at the St Gallen Breast Cancer Conference as a way to expand the range of individualized cancer drugs by revealing more pathways responsible for breast cancer response and outcome. Farbice André MD, PhD, from the Institut Gustave Roussy in Villejuif, France, discussed the scope for bridging the gap between new genomic technologies and their application in the real world with Oncology Times reporter Sarah Maxwell.
Share